Advertisement

Medical Therapy of Fistulizing Crohn’s Disease

  • Luigi Benini
  • Fosca De Iorio
  • Naika Tacchella
  • Italo Vantini

Conclusion

Treatment of CD fistulizing Crohn’s disease requires a close collaboration between the gastroenterologist and the surgeon. Antibiotics and immunomodulators such as azathioprine/6-mercaptopurine or methotrexate, if the patient is AZA-6MP intolerant/resistant, should be given early in the disease. In the case of resistance to immunomodulators, infliximab is the treatment of choice. Short-term cyclosporine A or tacrolimus may be tried in patients who fail to respond to infliximab. Abscesses should always be drained by an expert surgeon.

Keywords

Mycophenolate Mofetil Perianal Fistula Oral Tacrolimus Fistula Healing Intravenous Cyclosporine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Steinberg DM (1973) Abscess and fistulae in Crohn disease. Gut 14:865–869PubMedGoogle Scholar
  2. 2.
    Rankin GB (1979) National cooperative Crohn’s disease study: extraintestinal manifestations and perianal complications. Gastroenterology 77:914–20PubMedGoogle Scholar
  3. 3.
    Farmer RG (1975) Clinical patterns in Crohn’s disease: a statistical study of 615 patients. Gastroenterology 68:627–635PubMedGoogle Scholar
  4. 4.
    Sachar DB, Bodian CA, Goldstein ES et al (2005) Is perianal Crohn’s disease associated with intestinal fistulization? Am J Gastroenterol 100(7):1547–1549PubMedCrossRefGoogle Scholar
  5. 5.
    Bell SJ, Williams AB, Wiesel P, Wilkinson K, Cohen RCG, Kamm MA (2003) The clinical course of fistulating Crohn’s disease. Aliment Pharmacol Ther 17:1145–1151PubMedCrossRefGoogle Scholar
  6. 6.
    Schwartz DA (2002) The Natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 122:875–880PubMedCrossRefGoogle Scholar
  7. 7.
    Gray BK, Lockhartmummery HE, Morson BC (1965) Crohn’s disease of the anal region. Gut 6:515–524PubMedGoogle Scholar
  8. 8.
    Hellers G, Bergstrand O, Ewerth S, Holmstrom B (1980) Occurrence in outcome after primary treatment of anal fistulae in Crohn’s disease. Gut 21:525–527PubMedGoogle Scholar
  9. 9.
    Present DH (2000) How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 6:48–57PubMedCrossRefGoogle Scholar
  10. 10.
    Judge TA, Lichtenstein GR (2004) Treatment of fistulizing Crohn’s disease. Gastroenterol Clin N Am 33:421–454CrossRefGoogle Scholar
  11. 11.
    Sparberg M, Kirsner JB (1966) Long-term corticosteroid therapy for enteritis: an analysis of 58 courses in 54 patients. Am J Dig Dis 11:865–880PubMedCrossRefGoogle Scholar
  12. 12.
    Jones JH, Lennard-Jones JF (1966) Corticosteroids and corticotrophin in the treatment of Crohn’s disease. Gut 7:181–187PubMedGoogle Scholar
  13. 13.
    Malchow H, Ewe J, Brandes W et al (1984) European cooperative Crohn’s disease study (ECCDS): results of drug treatment. Gastroenterology 86:249–266PubMedGoogle Scholar
  14. 14.
    Agrawal A, Durrani S, Leiper K et al (2005) Effect of systemic corticosteroid therapy on risk for intraabdominal or pelvic abscess in non-operated Crohn’s disease. Clin Gastroenterol Hepatol 3:1215–1220PubMedCrossRefGoogle Scholar
  15. 15.
    Present DH (2002) Urinary tract fistulae in Crohn’s disease: surgery versus medical therapy. Am J Gastroenterol 97:2165–2167PubMedCrossRefGoogle Scholar
  16. 16.
    Ursing B, Kamme C (1975) Metronidazole for Crohn’s disease. Lancet 1:775–777PubMedCrossRefGoogle Scholar
  17. 17.
    Bernstein LH, Frank MS, Brandt LJ, Boley SJ (1980) Metronidazole therapy for perineal Crohn’s disease with metronidazole. Gastroenterology 79:357–365PubMedGoogle Scholar
  18. 18.
    Brandt LJ, Bernstein LH, Boley SJ, Frank MS (1982) Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology 83:383–387PubMedGoogle Scholar
  19. 19.
    Jakobovits J, Schuster MM (1984) Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol 79:533–540PubMedGoogle Scholar
  20. 20.
    Schneider MU, Laudage G, Guggenmoos-Holzma I, Riemann JF (1985) Metronidazol in der behandlung des morbus Crohn. Dtsch Med Wochenschr 110:1724–1930PubMedCrossRefGoogle Scholar
  21. 21.
    Arseneau KO, Cohn SM, Cominelli F, Connors AF Jr (2001) Cost-utility of initial medical management for Crohn’s disease perianal fistulae. Gastroenterology 120:1640–1656PubMedCrossRefGoogle Scholar
  22. 22.
    Duffy LF, Daum F, Fisher SE et al (1985) Peripheral neuropathy in Crohn’s disease patients treated with metronidazole. Gastroenterology 88:681–684PubMedGoogle Scholar
  23. 23.
    Turunen U, Farkkila M, Seppala K (1989) Long-term treatment of peri-anal or fistulous Crohn’s disease with ciprofloxacin. Scan J Gastroenterol 24:144–148Google Scholar
  24. 24.
    Solomon M, McLeod R, O’Connor B et al (1993) Combination ciprofloxacin and medronidazole in severe perianal Crohn’s disease. Can J Gastroenterol 7:571–573Google Scholar
  25. 25.
    Present DH, Korelitz BI, Wisch N et al (1980) Treatment of Crohn’s disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 302:981–987PubMedCrossRefGoogle Scholar
  26. 26.
    Korelitz BI, Present DH (1985) Favorable effect of 6-mercaptopurine on fistulae of Crohn’s disease. Dig Dis Sci 30:58–64PubMedCrossRefGoogle Scholar
  27. 27.
    Pearson DC, May GR, Fick GH, Sutherland LR (1995) Azathioprine and 6-mercaptopurine in Crohn’s disease: a meta-analysis. Ann Intern Med 123:132–142PubMedGoogle Scholar
  28. 28.
    Cuffari C, Hunt S, Bayless T (2001) Utilization of 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 48:642–646PubMedCrossRefGoogle Scholar
  29. 29.
    Present DH, Meltzer SJ, Krumholtz MP et al (1989) 6-mercaptopurine in the management of inflammatory bowel disease: short and long-term toxicity. Ann Intern Med 111:641–649PubMedGoogle Scholar
  30. 30.
    Mahadevan U, Marion JF, Present DH (2003) Fistula response to methotrexate in Crohn’s disease: a case series. Aliment Pharmacol Ther 18:1003–1008PubMedCrossRefGoogle Scholar
  31. 31.
    Vandeputte L, D’Haens G, Baert F, Rutgeerts P (1999) Methotrexate in refractory Crohn’s disease. Inflamm Bowel Dis 5:11–15PubMedCrossRefGoogle Scholar
  32. 32.
    Lemann M, Zenjari T, Bouhnik Y et al (2000) Methotrexate in Crohn’s disease: long-term efficacy and toxicity. Am J Gastroenterol 95:1730–1734PubMedGoogle Scholar
  33. 33.
    Te HS, Schiano TD, Kuan SF et al (2000) Hepatic effect of long-term methotrexate use in treatment of inflammatory bowel disease. Am J Gastroenterol 95:3150–3156PubMedCrossRefGoogle Scholar
  34. 34.
    Fukushima T, Sugita A, Masuzawa S et al (1989) Effects of cyclosporine A on active Crohn’s disease. Gastroenterol JPN 24:12–15PubMedGoogle Scholar
  35. 35.
    Lichtiger S (1990) Cyclosporine therapy in inflammatory bowel disease: open-label experience. Mt Sinai J Med 57:315–319PubMedGoogle Scholar
  36. 36.
    Hanauer SB, Smith MB (1993) Rapid closure of Crohn’s disease fistulae with continuous intravenous cyclosporine A. Am J Gastroenterol 88:646–649PubMedGoogle Scholar
  37. 37.
    Present DH, Lichtiger S (1994) Efficacy of cyclosporine in treatment of fistula of Crohn’s disease. Dig Dis Sci 39:374–380PubMedCrossRefGoogle Scholar
  38. 38.
    Markowitz J, Rosa J, Grancher K et al (1990) Longterm 6-mercaptopurine treatment in adolescents with Crohn’s disease. Gastroenterology 99:1347–1351PubMedGoogle Scholar
  39. 39.
    Abreu-Martin M, Vasiliauskas E, Gaiennie J (1996) Continuous infusion cyclosporine is effective for severe acute Crohn’s disease: but for how long? Gastroenterology 110:A851Google Scholar
  40. 40.
    O’Neill J, Pathhmakanthan S, Goh J (1997) Cyclosporine A induces remission in fistulous Crohn’s disease but relapse occurs upon cessation of treatment. Gastroenterology 112:A1056CrossRefGoogle Scholar
  41. 41.
    Hinterleitner TA, Petritsch W, Aichbichler B et al (1997) Combination of cyclosporine, azathioprine and prednisolone for perianal fistulae in Crohn’s disease. Z Gastroenterol 35:603–608PubMedGoogle Scholar
  42. 42.
    Egan LJ, Sandborn WJ, Tremaine WJ (1998) Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn’s disease with intravenous cyclosporine. Am J Gastroenterol 93:442–448PubMedCrossRefGoogle Scholar
  43. 43.
    Gurudu SR, Griffel LH, Gialanella RJ, Das KM (1999) Cyclosporine therapy in inflammatory bowel disease: short-term and long-term results. J Clin Gastroenterol 29:151–154PubMedCrossRefGoogle Scholar
  44. 44.
    Hinterleitner TA, Petritsch W, Aichbichler B, Fickert P, ranner G, Krejs GJ (1997) Combination of cyclosporine, azathioprine and prednisolone for perianal fistulae in Crohn’s disease. Z Gastroenterol 35:603–608PubMedGoogle Scholar
  45. 45.
    Sandborn W (1995) A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1:48–63CrossRefGoogle Scholar
  46. 46.
    Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ (1999) Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn’s disease perianal fistulae. Inflamm Bowel Dis 5:239–245PubMedCrossRefGoogle Scholar
  47. 47.
    Sandborn WJ (1997) Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn’s disease. Am J Gastroenterol 92:876–879PubMedGoogle Scholar
  48. 48.
    Fellermman K, Ludwig D, Stahl M et al (1998) Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 93:1860–1866CrossRefGoogle Scholar
  49. 49.
    Sandborn WJ, Present DH, Isaacs KL et al (2003) Tacrolimus for the treatment of fistulae with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology 126:942–943Google Scholar
  50. 50.
    Gonzalez-Lama Y, Abreu L, Vera MI et al (2005) Longterm tacrolimus therapy in refractory to infliximab fistulizing Crohn’s disease: a pilot study. Inflamm Bowel Dis 11:8–15PubMedCrossRefGoogle Scholar
  51. 51.
    Neurath MF, Wanitschke R, Peters M et al (1999) Randomized trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease. Gut 44:625–628PubMedCrossRefGoogle Scholar
  52. 52.
    Fickert P, Hinterleitner TA, Wenzl HH et al (1998) Mycophenolate mofetil in patients with Crohn’s disease. Am J Gastroenterol 93:2529–2532PubMedCrossRefGoogle Scholar
  53. 53.
    Miehsler W, Reinisch W, Moser G et al (2001) Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with active Crohn’s disease? Am J Gastroenterol 96:782–787PubMedCrossRefGoogle Scholar
  54. 54.
    Fellermann K, Steffen M, Steinn J et al (2000) Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 14:171–176PubMedCrossRefGoogle Scholar
  55. 55.
    Wenzl HH, Hinterleitneir TA, Aichbichler BW et al (2005) Mycophenolate mofetil for Crohn’s disease: short-term efficacy and long-term outcome. Aliment Pharmacol Ther 19:427–434CrossRefGoogle Scholar
  56. 56.
    Present DH, Rutgeerts P, Targann S et al (1999) Infliximab for the treatment of fistulae in patients with Crohn’s disease. N Engl J Med 340:1398–1405PubMedCrossRefGoogle Scholar
  57. 57.
    Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549PubMedCrossRefGoogle Scholar
  58. 58.
    Sands E, Anderson FH, Bernstein CN, Chey WY et al (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Eng J Med 350:876–885CrossRefGoogle Scholar
  59. 59.
    Hanauer SB (2005) Infliximab: lifetime use for maintenance is appropriate in Chron’s disease. CON: “lifetime use” is an awfully long time. Am J Gastroenterol 100:1435–1437CrossRefGoogle Scholar
  60. 60.
    Rutgeerts P, Feagna BG, Lichtenstein GR et al (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126:598–601CrossRefGoogle Scholar
  61. 61.
    Lichtenstein GR (2005) Infliximab: lifetime use for maintenance is appropriate in Crohn’s disease. Pro: maintenance therapy is superior to episodic therapy. Am J Gastroenterol 100:1433–1435PubMedCrossRefGoogle Scholar
  62. 62.
    Poritz LS, Rowe WA, Koltun WA (2002) Remicade does not abolish the need for surgery in fistulizing Crohn’s disease. Dis Colon Rectum 45:771–775PubMedCrossRefGoogle Scholar
  63. 63.
    Arseneau KO, Cohn SM, Cominelli F, Connors AF Jr (2001) Cost-utility of initial medical management for Crohn’s disease perianal fistulae. Gastroenterology 120:1640–1656PubMedCrossRefGoogle Scholar
  64. 64.
    Lichtenstein GR, Yan S, Bala M et al (2005) Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology 128:862–869PubMedCrossRefGoogle Scholar
  65. 65.
    Sandborn WJ, Feagan BG, Hanauer SB et al (2001) An engineered human antibody to TNF (CDP571) for active Crohn’s disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120:1330–1338PubMedCrossRefGoogle Scholar
  66. 66.
    Eherenpreis ED, Kane SV, Cohen LB et al (1999) Thalidomide therapy for patients with refractory Crohn’s disease: an open-label trial. Gastroenterology 117:1271–1277CrossRefGoogle Scholar
  67. 67.
    Vasiliauskas EA, Kam Ly, Abreu-Martin MT et al (1999) An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn’s disease. Gastroenterology 117:1278–1287PubMedCrossRefGoogle Scholar
  68. 68.
    Present DH (2003) Crohn’s fistula: current concepts in management. Gastroenterology 124:1629–1635PubMedCrossRefGoogle Scholar
  69. 69.
    Calam J, Crooks PE, Walker RJ (1980) Elemental diets in the management of Crohn’s perianal fistulae. JPEN 4:4–8Google Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • Luigi Benini
    • 1
  • Fosca De Iorio
    • 1
  • Naika Tacchella
    • 1
  • Italo Vantini
    • 1
  1. 1.Department of Biomedical and Surgical Sciences, Division of GastroenterologyPoliclinico “G.B. Rossi”VeronaItaly

Personalised recommendations